Table 1.
Summary statistics of psoriatic arthritis cohort at each visit
| Measures | Visit 1 N=100 | Visit 2 N=93 | Visit 3 N=84 | Visit 4 N=71 |
|---|---|---|---|---|
| Tender joint count [0-68], mean (SD) | 3.23 (4.87) | 3.97 (5.92) | 3.94 (4.95) | 5.66 (7.98) |
| Swollen joint count [0-66], mean (SD) | 3.08 (3.74) | 3.09 (3.78) | 3.65 (3.69) | 4.14 (5.16) |
| Enthesitis, n (%) | 7 (7) | 7 (7.53) | 8 (9.52) | 12 (16.90) |
| Dactylitis, n (%) | 3 (3) | 5 (5.38) | 4 (4.76) | 2 (2.82) |
| Psoriasis BSA [0-100], mean (SD) | 2.23 (4.73) | 3.07 (9.35) | 4.77 (12.03) | 3.03 (6.25) |
| Percent BSA ≥10, n (%) | 5 (5) | 5 (5.38) | 10 (11.90) | 6 (8.45) |
| Pain NRS [0-10], mean (SD) | 3.61 (2.87) | 3.45 (2.89) | 3.73 (3.13) | 3.48 (2.93) |
| Patient global psoriatic disease NRS [0-10], mean (SD) | 3.77 (3.18) | 3.29 (2.99) | 3.34 (2.99) | 3.53 (2.98) |
| Patient global psoriatic arthritis NRS [0-10], mean (SD) | 3.79 (3.02) | 3.33 (2.87) | 3.31 (2.95) | 3.57 (2.98) |
| PROMIS-PF4a [0-100], T-score mean (SD) | 43.03 (9.39) | 44.15 (9.74) | 43.70 (9.86) | 45.15 (9.71) |
| PROMIS-PF CAT [0-100], T-score mean (SD) | 43.76 (10.29) | 45.02 (9.97) | 44.49 (10.23) | 44.85 (9.46) |
| HAQ-DI [0-3], mean (SD) | 0.71 (0.76) | 0.61 (0.70) | 0.68 (0.73) | 0.64 (0.73) |
| HAQ-DI=0, n (%) | 25 (25) | 30 (32.26) | 25 (29.76) | 23 (32.39) |
| MDA HAQ-DI, n (%) | 43 (43) | 47 (57.32) | 33 (45.21) | 28 (48.28) |
| MDA PROMIS-PF4a, n (%) | 43 (43) | 43 (51.81) | 31 (42.47) | 28 (46.67) |
| MDA PROMIS-PF CAT, n (%) | 43 (43) | 46 (54.76) | 33 (44.59) | 31 (51.67) |
| VLDA HAQ-DI, n (%) | 9 (9) | 11 (11.83) | 10 (11.90) | 9 (12.68) |
| VLDA PROMIS-PF4a, n (%) | 9 (9) | 11 (11.83) | 10 (11.90) | 9 (12.68) |
| VLDA PROMIS-PF CAT, n (%) | 10 (10) | 12 (12.90) | 10 (11.90) | 9 (12.68) |
| cDAPSA T2T state, n (%) | 53 (53) | 54 (63.53) | 45 (55.56) | 34 (54.29) |
| Biologicals alone or in DMARD combination, n (%) | 56 (56) | 58 (62.37) | 58 (69.05) | 52 (73.34) |
| DMARD alone, n (%) | 25 (25) | 25 (26.88) | 17 (20.24) | 15 (21.13) |
Abbreviations
SD: Standard Deviation; NRS: Numeric Rating Scale; HAQ-DI: Heath Assessment Questionnaire-Disability Index; PROMIS-PF 4a: Patient Reported Outcomes Measurement Information System Short Form v2.0 Physical Function 4a; PROMIS-PF CAT: PROMIS Bank v1.2 – Physical Function Computer Adaptive Test; BSA: body surface area affected by psoriasis; MDA HAQ-DI: Minimal disease activity that includes the HAQ-DI ≤0.5 criterion; MDA PROMIS-PF4a includes the PROMIS-PF4a T-score ≥41.3 criterion; MDA PROMIS-PF CAT includes the PROMIS-PF CAT T-score ≥41.3 criterion; VLDA Very Low Disease Activity, VLDA variables similarly defined to MDA variables; cDAPSA: clinical disease activity psoriatic arthritis; T2T: treat-to-target; DMARD: disease modifying anti-rheumatic drug.